Data Context: What We Actually Know
Important: data limitations
All formal safety data for TB-500 comes from animal studies. Human safety information derives entirely from anecdotal self-reports and a limited number of small clinical studies using topical Thymosin Beta-4 (e.g., eye drops) — not systemic injectable TB-500. The injectable TB-500 used in research communities has no formal human safety trial data.
Side Effects by Severity
MildModerateSevere / Serious
Injection site irritation (redness, minor swelling)Mild
Frequency: Common — estimated 20–30% of users anecdotally
Normal reaction to subcutaneous injection. Rotate sites, use proper technique.
Temporary lethargy or fatigue post-injectionMild
Frequency: Common — reported by approximately 15–25% of users anecdotally
Often noted within 1–2 hours of injection, usually resolving within a day. May be related to inflammatory modulation.
HeadacheMild
Frequency: Rare (<10% anecdotally)
Transient, typically resolving within hours.
NauseaMild
Frequency: Rare (<5% anecdotally)
Less common than with BPC-157. Usually dose-related.
Vasodilation (rush of warmth or blood to the head)Mild
Frequency: Rare (<5% anecdotally)
Likely due to angiogenic/vasodilatory mechanism. Transient.
Contraindications
- ✕Active malignancy (theoretical proliferative risk via cell migration mechanism)
- ✕Pregnancy and breastfeeding (no safety data)
- ✕Pediatric use (no safety data)
- ✕Known hypersensitivity to Thymosin Beta-4 or peptide excipients
Drug Interactions
No formal pharmacokinetic drug interaction studies have been conducted for most research peptides. The interactions below are theoretical, mechanism-based, or derived from limited case reports.
- ⚠Anticoagulants: potential additive effect via actin-mediated platelet function — theoretical, not confirmed in studies
- ⚠Cancer chemotherapy: TB-500's pro-migratory cell effects may theoretically interfere with chemotherapy mechanisms — contraindicated in active cancer treatment
- ⚠Other healing peptides (BPC-157, GHK-Cu): commonly stacked; complementary mechanisms, no known adverse interactions
- ⚠No formal pharmacokinetic drug interaction studies have been conducted
Frequently Asked Questions
Is TB-500 safe for humans?
TB-500 has an excellent preclinical safety profile — extensive animal studies have found no significant organ toxicity or adverse effects at therapeutic doses. The small clinical human experience (primarily with Thymosin Beta-4 eye drops) has been well-tolerated. However, injectable systemic TB-500 has no completed human Phase I safety trials. The anecdotal human experience is generally favorable, but this is insufficient to establish formal safety.
Can TB-500 cause cancer?
This is the primary theoretical concern. TB-500 promotes cell migration and proliferation via actin upregulation — the same mechanisms that cancer cells exploit. No animal studies have shown TB-500 causes or accelerates cancer. The concern is theoretical and precautionary. Individuals with active cancer or a strong cancer history should avoid use until more safety data is available.
What are the side effects of TB-500 injection?
The most commonly reported effects are: injection site irritation (redness, swelling, minor pain), temporary fatigue within hours of injection, occasional headache, and rarely nausea. These effects are generally mild and transient. No serious adverse events have been confirmed in preclinical or limited human data. Proper sterile injection technique reduces injection site risks significantly.
Does TB-500 cause fatigue?
A notable minority of users report temporary lethargy or tiredness in the hours following an injection. This is thought to relate to TB-500's anti-inflammatory activity — similar to the fatigue sometimes experienced after other immunomodulatory treatments. It typically resolves within 24 hours and is less common with lower doses.
Is TB-500 safe to use long-term?
Long-term human safety data for systemic injectable TB-500 does not exist. Chronic animal studies have not shown organ toxicity. The standard cautious approach is to use defined cycles (loading phase + maintenance) with breaks in between rather than continuous indefinite use. Regular bloodwork monitoring is sensible for anyone on extended peptide protocols.
References
Last updated: 2026-02-26